• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current therapeutic research, clinical and experimental. >Risk Factors for Thrombocytopenia in Adult Chinese Patients Receiving Linezolid Therapy
【24h】

Risk Factors for Thrombocytopenia in Adult Chinese Patients Receiving Linezolid Therapy

机译：接受利奈唑胺治疗的中国成年患者血小板减少症的危险因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Linezolid (LZD), an oxazolidinone antibiotic agent, has excellent activity and bio-availability against most methicillin-sensitive and methicillin-resistant gram-positive bacteria. Although LZD is generally well tolerated, studies have found associated adverse hematologic effects such as thrombocytopenia, anemia, and hematocytopenia. Of these, thrombocytopenia is of most concern. Linezolid has been available in China since 2007, and many instances of LZD-associated thrombocytopenia have recently been reported in China. However, the incidence of and risk factors for LZD-induced thrombocytopenia in a large sample of Chinese have not been reported to date. Moreover, the incidence of LZD-related thrombocytopenia varies between countries such as the United States and Japan. The present retrospective cross-sectional study was performed to investigate the risk factors for thrombocytopenia in adult Chinese patients who received LZD therapy, to screen for important clinical features that can be used to predict the incidence of thrombocytopenia, to provide a reasonable assessment of the risk of LZD-related thrombocytopenia in the Chinese population, and to reduce the incidence of serious adverse reactions.
机译：恶唑烷酮抗生素药利奈唑胺（LZD）对大多数对甲氧西林敏感和耐甲氧西林的革兰氏阳性菌具有出色的活性和生物利用度。尽管LZD通常具有良好的耐受性，但研究发现相关的不利血液学影响，例如血小板减少症，贫血和血细胞减少症。其中，血小板减少症是最令人关注的。利奈唑胺从2007年开始在中国上市，最近在中国报道了许多与LZD相关的血小板减少症的病例。然而，迄今为止，尚未有大量中国人样本中LZD诱导的血小板减少症的发生率和危险因素的报道。此外，LZD相关血小板减少症的发生率在美国和日本等国家之间也有所不同。本回顾性横断面研究旨在调查接受LZD治疗的中国成年患者血小板减少的危险因素，以筛选可用于预测血小板减少发生率的重要临床特征，从而合理评估风险LZD相关的血小板减少症在中国人群中的发生，并减少严重不良反应的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号